Drug Insight: clopidogrel nonresponsiveness
Paul A Gurbel* and Udaya S Tantry
Correspondence *Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA
Email pgurbel@lifebridgehealth.org
Clopidogrel is widely used during percutaneous coronary intervention and to treat acute coronary syndromes. Nonresponsiveness and variability in responsiveness to clopidogrel therapy have been noted in numerous studies, and could put some patients at risk of repeat thrombotic events. The possible mechanisms and ways to overcome poor response to clopidogrel are discussed here.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
